Ibrutinib tablet splitting as a practical strategy for dose reduction in the management of drug–drug interactions
Open accessAbstract
Background: Ibrutinib exposure is strongly affected by cytochrome P450 3A4 (CYP3A4) activity. Drug-drug interactions (DDIs) can substantially increase ibrutinib plasma concentrations, requiring major dose reductions in DDI management. This study aimed to assess whether splitting ibrutinib 140 mg tablets is a practical and feasible strategy to adjust ibrutinib dosing in case of DDIs. Methods: Ibrutinib 140 mg tablets were split into quarters using a tablet splitter aiming at 35 mg dose units. The obtained quarters were evaluated according to the European Pharmacopoeia requirements for Uniformity of Dosage Units. In addition, Uniformity of Mass, Uniformity of Content, loss of mass, stability of quartered tablets, reproducibility of splitting, usability of the splitting device, and patient instructions were assessed. The expected effects of tablet splitting on ibrutinib exposure were calculated. Results: A strong correlation between tablet mass and ibrutinib content was observed ( r = 0.896; p < 0.0001), indicating uniform distribution of ibrutinib throughout the tablets. Loss of mass was <3% for all tablets, indicating that quartering did not lead to substantial material loss. The mean ibrutinib content was 34.4 mg (range 28.2–40.3 mg). Uniformity of Dosage Units of ibrutinib quarters complied with the European Pharmacopoeia requirements, with an acceptance value of 7.5% against a requirement of ≤15%. Split tablets were stable for at least two weeks under outpatient storage conditions. Patient instructions were considered sufficient and the splitting device was rated user-friendly. The impact of splitting variation on exposure is within the range of interindividual variation in ibrutinib exposure. Conclusion: Splitting ibrutinib 140 mg tablets may provide a practical, clinically feasible and patient-friendly strategy to obtain 35 or 70 mg doses of ibrutinib when dose reduction is required in the management of DDIs. The expected exposure variation due to dose variations introduced by tablet splitting is unlikely to be of clinical relevance.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · see citing works
Mato, A. R., Nabhan, C., Thompson, M. C., Lamanna, N., Brander, D. M., Hill, B. T., Howlett, C., Skarbnik, A. P. Z., Cheson, B. D., Zent, C. S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.182907 · Cited by 460 · see citing works
Tablet-splitting: a common yet not so innocent practice
Verrue, C., Mehuys, E., Boussery, K., Remon, J.-P., & Petrovic, M. (2011) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2010.05477.x · Cited by 134 · see citing works
The frequency of inappropriate tablet splitting in primary care
Quinzler, R., Gasse, C., Schneider, A., et al. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0202-3 · Cited by 127 · see citing works
Effect of CYP 3A perpetrators on ibrutinib exposure in healthy participants
de Jong, J., Skee, D. M., Murphy, J., Sukbuntherng, J., Hellemans, P., Smit, J. W., de Vries, R., Jiao, J. J., Snoeys, J., & Mannaert, E. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.156 · Cited by 103 · see citing works
Accuracy of tablet splitting: Comparison study between hand splitting and tablet cutter
Habib, W. A., Alanizi, A. S., Abdelhamid, M. M., & Alanizi, F. K. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.12.014 · Cited by 81 · see citing works
de Jong, J., Hellemans, P., Wilde, S. D., Patricia, D., Masterson, T. J., Manikhas, G., Myasnikov, A., Шевкетович, О. Д., Córdoba, R., Panizo, C., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1460474 · Cited by 52 · see citing works
Ibrutinib dose modifications in the management of CLL
Hardy-Abeloos, C., Pinotti, R., & Gabrilove, J. L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00870-w · Cited by 48 · see citing works
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
Gayko, U., Fung, M., Clow, F., Sun, S. H., Faust, E. A., Price, S., James, D. F., Doyle, M., Bari, S., & Zhuang, S. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12878 · Cited by 47 · see citing works
Tapaninen, T., Olkkola, A. M., Tornio, A., Neuvonen, M., Elonen, E., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12716 · Cited by 44 · see citing works
The tablet splitter: Barrier to compliance or cost-saving instrument?
Carr‐Lopez, S. M., Mallett, M. S., & Morse, T. (1995) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/52.23.2707 · Cited by 30 · see citing works
Pharmacokinetic Boosting of Kinase Inhibitors
Westra, N., Touw, D. J., Hooge, M. N. L., Kosterink, J. G. W., & Munnink, T. H. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041149 · Cited by 23 · see citing works
Self-citationGallais, F., Ysebaert, L., Despas, F., et al. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00884-0 · Cited by 21 · see citing works
Woerdenbag, H. J., Visser, J., Reinink, M. P. A. M. L. O., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020320 · Cited by 21 · see citing works
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
Eisenmann, E. D., Fu, Q., Muhowski, E. M., Jin, Y., Uddin, M. E., Garrison, D. A., Weber, R. H., Woyach, J. A., Byrd, J. C., Sparreboom, A., et al. (2021) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0076 · Cited by 18 · see citing works
Concerns regarding tablet splitting: a systematic review
Saran, A. K., Holden, N. A., & Garrison, S. (2022) · BJGP Open · doi:10.3399/bjgpo.2022.0001 · Cited by 18 · see citing works
Does splitting a tablet obtain the accurate dose?: A systematic review protocol
Chaudhri, K., Kearney, M., Di Tanna, G. L., Day, R. O., Rodgers, A., & Atkins, E. R. (2019) · Medicine · doi:10.1097/md.0000000000017189 · Cited by 15 · see citing works
Tablet Splitting: Imperfect Perhaps, but Better than Excessive Dosing
Cohen, J. S. (2002) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658002763508443 · Cited by 13 · see citing works
Li, C., Chen, L., Li, L., & Chen, W. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106564 · Cited by 9 · see citing works
Ouerdani, A., Valenzuela, B., Treijtel, N., Haddish‐Berhane, N., Desphande, S., Srinivasan, S. S., Smith, E., & Ruixo, J. J. P. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04753-0 · Cited by 9 · see citing works
Olkkola, A. M., Tapaninen, T., Tornio, A., Hauta‐aho, M., Lapatto‐Reiniluoto, O., Neuvonen, M., Kiiski, J. I., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15932 · Cited by 6 · see citing works
Flagged first, then by citations
Research works printed but not linked: 7
- U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research. Clinical Pharmacology and biopharmaceutics review(s): Pharmacometric Review. Application number 205552Orig2s000. Silver Spring (MD): FDA; 2014. Available from: FDA pharmacometric review (ibrutinib).
- Council of Europe. European pharmacopoeia (Ph. Eur.) 11th Edition - Monograph Tablets. 2023.
- Council of Europe. European pharmacopoeia (Ph. Eur.) 11th Edition - Monograph Uniformity of mass. Published online April 2023.
- Council of Europe. European pharmacopoeia (Ph. Eur.) 11th Edition - Monograph Uniformity of content. Published online April 2023.
- Council of Europe. European pharmacopoeia (Ph. Eur.) 11th Edition - Monograph Uniformity of Dosage Units. 2023.
- Seong S, Shin JY, Kim D, et al. The effect of tablet splitting on the mass loss, uniformity, and stability: by hand or splitter? Journal of Asian Association of Schools of Pharmacy 2019; 8: 7–14.
- 10.3390/pharmaceutics15041149 · DOI
Cited by
Still being checked.
- Authors
- Jager, L., Koopmans, P., Westra, N., Nijland, M., Hooge, M. L.-D., & Munnink, T. O.
- Affiliations
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- University Medical Centre Groningen
- Venue
- Journal of Oncology Pharmacy Practice
- Publisher
- SAGE Publications
- Published
- 2026-08-20
- Pages
- 10781552261478573-10781552261478573
- ISSN
- 1078-1552 (ISSN-L)
- 1477-092X
- OpenAlex
- W7203829155
- Semantic Scholar
- c504e1d612d248eb41a0c224e23b08c5cd7692b8
- Cited by
- 0
- References
- 21
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Oncology Pharmacy Practice (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- ibrutinib, tablet splitting, drug-drug interactions, dose reduction, CYP3A4, uniformity of dosage units, tablet stability, patient instructions, BTK inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
